Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT01720719

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as a collaborator
Registry
  • NCT NCT01720719
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01720719. Randomized; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
Condition
Fatty Liver
Condition
Dyslipidemias
Condition
Diabetes Mellitus
Intervention (Drug)
atorvastatin
Intervention (Drug)
Vitamin E
Lead sponsor
Xin Gao (class: other)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01720719
Content hash
30a414b9dfdfd4399c35176f94ef59aadebf0b964806fce784325aacb1bef4a1